Since 2015, three agents of immunotherapy, either PD-1 or PD-L1 antibodies, have been approved by the FDA to be used in the treatment of lung cancer patients, for they all showed some effect in prolonging the survival rates of lung cancer patients with or without driver gene mutation [5–9]. This evidence concerns the gene CD274 and lung carcinoma.